Microcap Ledger Tempest Therapeutics, Inc. $TPST
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Brisbane, CA
- Fiscal year end
- December 31
- Shares outstanding
- 14,806,997 [10-Q 2026-05-14]
What the company doesAI summary of filing
Tempest Therapeutics is a clinical-stage biotechnology company developing a portfolio of cell therapy and small molecule product candidates for cancer and immunology indications. The company's lead program is TPST-2003, an autologous dual-targeting CAR-T therapy in clinical development for relapsed or refractory multiple myeloma, along with additional CAR-T candidates in earlier stages. The company also develops two small-molecule programs: amezalpat, which has completed Phase 2 studies in hepatocellular carcinoma and is Phase 3-ready pending business development discussions, and TPST-1495, which is expected to enter a Phase 2 study in familial adenomatous polyposis in 2026 with external funding support. The company is pre-revenue and funds development through strategic partnerships, external funding sources, and equity. [10-K 2026-03-30]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$32.94M | −$10.38M | $779.0K | [10-Q 2026-08-13] |
| FY ended Dec 2025 | — | −$26.26M | −$26.82M | $7.71M | [10-K 2026-03-30] |
| FY ended Dec 2024 | — | −$41.84M | −$33.03M | $30.27M | [10-K 2026-03-30] |
- Quarterly cash burn
- −$5.19M
- Cash runway Estimate
- ~0.5 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-08 | 43,642,072 | [10-Q 2024-11-12] |
| 2025-03-21 | 45,483,384 | [10-K 2025-03-27] |
| 2025-04-25 | 3,655,015 | [10-K/A 2025-04-30] |
| 2025-05-08 | 3,682,428 | [10-Q 2025-05-13] |
| 2025-08-04 | 4,440,161 | [10-Q 2025-08-11] |
| 2025-10-30 | 4,440,161 | [10-Q 2025-11-05] |
| 2026-03-25 | 14,344,034 | [10-K 2026-03-30] |
| 2026-05-08 | 14,806,997 | [10-Q 2026-05-14] |
- Shelf registration
- S-3 filed 2026-09-25; declared effective 2026-10-01 [S-3 2026-09-25]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-05-22. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-05-22 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-05-22] |
| 2026-01-09 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-01-09] |
| 2024-12-31 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-12-31] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-03-24 | Angel Matthew | buy | 231,482 | $2.16 | [4 2026-06-23] |
| 2026-03-24 | Angel Matthew | buy | 231,482 | $2.16 | [4 2026-03-25] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-02 | 424B3 | Prospectus or prospectus supplement |
| 2026-09-28 | 8-K | Material agreement entered; Director or officer change; Regulation FD disclosure |
| 2026-09-25 | S-3 | Registration statement |
| 2026-09-17 | 8-K | Material agreement entered; Regulation FD disclosure |
| 2026-09-16 | 8-K | Shareholder vote results; Other events |
| 2026-09-15 | 8-K | Material agreement entered; Unregistered sale of equity |
| 2026-09-01 | 424B3 | Prospectus or prospectus supplement |
| 2026-08-24 | 8-K | Director or officer change |
| 2026-08-21 | S-1 | Registration statement |
| 2026-08-18 | 8-K | Shareholder vote results; Other events |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 8-K | Results of operations |
Alerts for $TPST
Email me when Tempest Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.